When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement
Open accessThe DOI matches its Crossref record; 136 of the 155 references it cites were found in a registry or an index; 16 of the 152 sources its claims cite were checked for support.
Abstract
A network of endometriosis experts from 16 Italian academic departments and teaching hospitals distributed all over the country made a critical appraisal of the available evidence and definition of 10 suggestions regarding measures to be de-implemented. Strong suggestions were made only when high-quality evidence was available. The aim was to select 10 low-value medical interventions, characterized by an unfavorable balance between potential benefits, potential harms, and costs, which should be discouraged in women with endometriosis. The following suggestions were agreed by all experts: do not suggest laparoscopy to detect and treat superficial peritoneal endometriosis in infertile women without pelvic pain symptoms; do not recommend controlled ovarian stimulation and IUI in infertile women with endometriosis at any stage; do not remove small ovarian endometriomas (diameter <4 cm) with the sole objective of improving the likelihood of conception in infertile patients scheduled for IVF; do not remove uncomplicated deep endometriotic lesions in asymptomatic women, and also in symptomatic women not seeking conception when medical treatment is effective and well tolerated; do not systematically request second-level diagnostic investigations in women with known or suspected non-subocclusive colorectal endometriosis or with symptoms responding to medical treatment; do not recommend repeated follow-up serum CA-125 (or other currently available biomarkers) measurements in women successfully using medical treatments for uncomplicated endometriosis in the absence of suspicious ovarian cysts; do not leave women undergoing surgery for ovarian endometriomas and not seeking immediate conception without post-operative long-term treatment with estrogen–progestins or progestins; do not perform laparoscopy in adolescent women (<20 years) with moderate–severe dysmenorrhea and clinically suspected early endometriosis without prior attempting to relieve symptoms with estrogen–progestins or progestins; do not prescribe drugs that cannot be used for prolonged periods of time because of safety or cost issues as first-line medical treatment, unless estrogen–progestins or progestins have been proven ineffective, not tolerated, or contraindicated; do not use robotic-assisted laparoscopic surgery for endometriosis outside research settings. Our proposal is to better address medical and surgical approaches to endometriosis de-implementing low-value interventions, with the aim to prevent unnecessary morbidity, limit psychological distress, and reduce the burden of treatment avoiding medical overuse and allowing a more equitable distribution of healthcare resources.
Overview
CoChat Summary
TL;DR
This ETIC position statement identifies 10 low-value diagnostic or therapeutic interventions in endometriosis that should generally be discouraged to reduce unnecessary morbidity, psychological distress, treatment burden, and healthcare costs. The authors used expert consensus and GRADE appraisal, making strong-against suggestions only when high-quality evidence was available.
Key findings
- The paper lists 10 “don’ts”: avoid laparoscopy for superficial peritoneal endometriosis in infertile women without pelvic pain; avoid controlled ovarian stimulation and IUI in endometriosis-associated infertility at any stage; avoid removing small ovarian endometriomas (<4 cm) solely to improve conception before IVF; avoid removing uncomplicated deep endometriotic lesions in asymptomatic women or when medical treatment is effective and well tolerated; avoid systematic second-level diagnostic investigations for known/suspected non-subocclusive colorectal endometriosis or symptoms responding to medical treatment; avoid repeated serum CA-125 or other biomarker follow-up in women successfully using medical treatment for uncomplicated endometriosis without suspicious ovarian cysts; do not omit post-operative long-term estrogen–progestins or progestins after surgery for ovarian endometriomas in women not seeking immediate conception; avoid laparoscopy in adolescent women (<20 years) with moderate–severe dysmenorrhea and clinically suspected early endometriosis before trying estrogen–progestins or progestins; avoid drugs unsuitable for prolonged use as first-line medical treatment unless estrogen–progestins or progestins are ineffective, not tolerated, or contraindicated; and avoid robotic-assisted laparoscopic surgery for endometriosis outside research settings.
- Evidence grading: quality was high for four topics, moderate for three, and low for three; suggestions were strong-against for four issues and weak-against for six. Strong suggestions were made only when high-quality evidence against an intervention was available.
- For laparoscopy in infertile women with superficial peritoneal endometriosis, meta-analytic ORs for ongoing pregnancy or live birth were 1.64 (95% CI 1.05–2.57) and 1.94 (95% CI 1.20–3.16); the number needed to treat was 12 and 8, rising to more than 24 or 16 given ≤50% prevalence of minimal/mild endometriosis among women with unexplained infertility, compared with IVF success ~25% and NNT of four.
- For post-operative endometrioma recurrence, the pooled OR was 0.12 (95% CI 0.05–0.29) in long-term oral contraceptive users versus never users; CA-125 for recurrence had sensitivity 15% and specificity 100%, versus pain relapse 71% and 80%, and abnormal physical examination 82% and 41%; TVS for rectosigmoid endometriosis had sensitivity 91% and specificity 98%.
Methods
- ETIC network experts from 16 Italian university departments and teaching hospitals participated; a steering committee circulated emails, and a provisional list was refined at a 2-day meeting in Verona on 28–29 October 2016, with 10 self-selected sub-groups each addressing one topic.
- Sub-groups performed literature searches and critically appraised evidence, also consulting major society guidelines; GRADE was used to classify quality of evidence as high, moderate, low, or very low, and suggestions as strong or weak, with only “weak-against” and “strong-against” considered.
- Draft reports were circulated by email and discussed at a second 2-day meeting in Frascati on 31 March–1 April 2017, then revised and approved at a third meeting in Catanzaro on 24–25 November 2017; the consensus process was financially supported by IBSA Institut Biochimique SA.
Limitations
- The paper states that a possible limitation is potential influence from Italian local costs and availability of procedures, since all participants were Italian; it also states that selection of the 10 points was based on expert opinion rather than a robust scientific approach, that other excluded points could be similarly or more important, and that the list is not exhaustive.
- The paper notes that three of the 10 suggestions (the fifth, sixth, and eighth) are based on low-quality evidence, though experts agreed overtesting/overdiagnosis is frequent in those circumstances.
- Evident from the text: the process was a qualitative consensus exercise rather than a pre-planned, registered quantitative systematic review, and it received financial support from a pharmaceutical company; one participant declared grants from Ferring and Serono.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 2 Not valid · 89 Not checked · 50 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Management of endometriosis is often dictated by personal convictions of physicians (and patients) and by local diagnostic–therapeutic paths and expertise (or lack of), rather than by robust evidence derived from adequately designed and conducted pragmatic, randomized, controlled trials (RCT) (Vercellini et al., 2015).”
§ When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement > Introduction
What the sources say
- Supportedcites Vercellini et al., 2015 source
The Abstract states that high-quality evidence 'is not always the case in the endometriosis field' and that 'in many clinical circumstances, healthcare decisions in women with endometriosis are taken based on suboptimal evidence', which carries the claim's core contrast with robust RCT-derived evidence. The Conclusion reinforces the 'personal convictions' element by urging physicians to communicate quantitative information from guidelines and systematic reviews 'and, preferably, not based on single studies or solely personal experience', and by making the patient's own priorities part of the shared decision; the section 'Unresolved issues regarding diagnosis: diagnostic delay or diagnostic inexperience?' and the suggestions to refer to 'a centre of expertise' and to build multidisciplinary referral teams cover the local pathways/expertise (or lack of) component. Trial-design shortcomings (superiority designs, patient-important comparators, poor publication of registered trials) supply the 'adequately designed and conducted' qualifier, so the paraphrase is faithful in substance though compressed from several sections. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, TVS showed a better agreement with histology then DCBE (Cohen’s K, 0.413 versus 0.04).”
§ When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement > The 10 ‘Don’ts’ in Endometriosis Management > Do not systematically request second-level diagnostic investigations in women with known or suspected non-subocclusive colorectal endometriosis or with symptoms responding to medical treatment (quality of the evidence, low; weak suggestion)
What the sources say
- Partly supportedcites Savelli et al., 2011 sourceExperimental — accuracy not yet measured
The Results and Table 3 report better agreement with histology for TVS than DCBE, but the cited Cohen’s κ values apply specifically to the bowel-DIE-only subgroup, not all posterior-compartment cases. Table 3 gives 0.413 versus 0.049, rather than 0.04; for overall posterior DIE, it gives 0.248 versus 0.031. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Women who underwent repeat surgery were more likely to need assisted conception and reported more irregular menstrual cycles associated with FSH concentrations ≥14 UI/ml (Fedele et al., 2006; Gelbaya and Nardo, 2011).”
§ When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement > The 10 ‘Don’ts’ in Endometriosis Management > Do not leave women undergoing surgery for ovarian endometriomas and not seeking immediate conception without post-operative long-term treatment with estrogen–progestins or progestins (quality of the evidence, high; strong suggestion)
What the sources say
- Supportedcites Fedele et al., 2006 source
The Results passage reports that assisted reproduction was used by 50% of women after repeat surgery versus 32.2% after primary surgery. It also reports more irregular cycles with elevated FSH in the repeat-surgery group. Neither difference was statistically significant, so the claim describes an observed tendency rather than an established increase in need. (LLM, conf=0.91)
- Not checked yetcites Gelbaya and Nardo, 2011 source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, considering that generally the healthcare resources are finite, adopting unjustifiably expensive technologies displaces resources in other similar patients, with a net decrease in population health (Paulden, 2017).”
§ When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement > Discussion
What the sources say
- Partly supportedcites Paulden, 2017 sourceExperimental — accuracy not yet measured
Section 4 explains that, under a fixed NHS budget, spending on technologies above the estimated opportunity-cost threshold can produce health losses greater than the gains. Sections 5 and 6 say the displaced patients may include people with similar characteristics, but NICE does not know who they are. The claim overstates that possibility as though the displaced resources necessarily come from similar patients; the paper also describes the net population-health decrease as expected, not certain. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Progestins can be used in women with metabolic or cardiovascular contraindications to estrogen–progestins and limit the risk of post-operative dysmenorrhea recurrence also when released locally via an intrauterine system (Strowitzki et al., 2010; Brown et al., 2012; Petraglia et al., 2012; Abou-Setta et al., 2013).”
§ When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement > The 10 ‘Don’ts’ in Endometriosis Management > Do not prescribe drugs that cannot be used for prolonged periods of time because of safety or cost issues as first-line medical treatment, unless estrogen–progestins or progestins have been proven ineffective, not tolerated, or contraindicated (quality of the evidence, high; strong suggestion)
What the sources say
- Could not verifycites Strowitzki et al., 2010 sourceExperimental — accuracy not yet measured
Our copy of Strowitzki et al. (2010) is a 24-week head-to-head trial of ORAL dienogest 2 mg/day versus depot leuprolide acetate in women with endometriosis-associated pain (Abstract; Study design); it contains no reference to an intrauterine system, local delivery of a progestin, or to reducing dysmenorrhea recurrence after surgery. Searches for 'intrauterine system / local release' and 'post-operative recurrence of dysmenorrhea' returned only the trial's pain-outcome and progestin-safety passages plus its reference list. The closest text is the Introduction's statement that 'reported recurrence rates after surgical therapy are high (Guo, 2009)', which is background credited to another work and says nothing about an IUS; the progestin passages (Introduction, Discussion) concern weight gain, androgenicity, BMD and irregular bleeding with oral/depot progestins, not post-operative recurrence prevention. (LLM, conf=0.72)
- Not checked yetcites Brown et al., 2012
- Partly supportedcites Petraglia et al., 2012 sourceExperimental — accuracy not yet measured
Petraglia et al. (2012) report their own data only for ORAL dienogest 2 mg/day: women with histologically proven endometriosis at laparoscopy ≤12 months before entry showed a significant, sustained fall in endometriosis-associated pelvic pain VAS (Results, 'Pelvic pain'; Abstract Conclusions), which supports the 'progestin limits post-operative pain recurrence' half of the sentence. The 'released locally via an intrauterine system' half is not this study: the Introduction states only that 'The LNG-intrauterine device (LNG-IUD) is an effective treatment for rectovaginal endometriosis in women who have previously undergone conservative surgery without excision of deep lesions [11]' — a background statement credited to reference 11 (Lockhat et al., Hum Reprod 2004) — and adds that the LNG-IUD is not approved for endometriosis. No dysmenorrhea-specific recurrence endpoint appears in our copy (pain is the composite EAPP VAS). (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
69 more claims · 2 with their cited sources checked
Create a free account to see all 152 claims and to verify the 131 references still open.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“COCs are currently used off label for the treatment of endometriosis, however they are commonly used as empirical therapy for women with suspect of endometriosis, without a confirmed surgical diagnosis of the disease [242].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [242]
Experimental — accuracy not yet measured
Citations
Cites
1 retracted
Laparoscopic surgery for subfertility associated with endometriosis
Jacobson, T. Z., Duffy, J. M., Barlow, D. H., Farquhar, C., Koninckx, P. R., & Olive, D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001398.pub2 · Cited by 359
RetractedGRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211 · cited 21×
“Overall, first-cycle chance of pregnancy with IVF is significantly higher than the cumulative pregnancy rate that can be obtained after six IUI cycles (Dmowski et al., 2002).”
BackgroundMethodInfluentialGrading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Laparoscopic Surgery in Infertile Women with Minimal or Mild Endometriosis
Marcoux, S., Maheux, R., & Bérubé, S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370401 · Cited by 948
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719 · cited 1×
“…long-term treatment with estrogen–progestins or progestins (quality of the evidence, high; strong suggestion) A cyst recurrence rate of ∼10% per year has been reported after surgery for ovarian endometriomas (Chapron et al., 2002; Koga et al., 2006; Liu et al., 2007; Guo, 2009; Koga et al., 2015).”
BackgroundPreventing overdiagnosis: how to stop harming the healthy
Moynihan, R., Doust, J., & Henry, D. (2012) · BMJ · doi:10.1136/bmj.e3502 · Cited by 675 · cited 1×
“harms, and cost of healthcare interventions (Moynihan et al., 2012; Colla, 2014).”
BackgroundEndometriosis and infertility: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.05.031 · Cited by 633 · cited 9×
“When endometriosis is suspected in adolescent women, nonsteroidal anti-inflammatory drugs and very low-dose OCs should be started without delay (American College of Obstetricians and Gynecologists (ACOG), 2005; Laufer, 2008; Saridogan, 2017; Zannoni et al., 2016), similar to what is generally suggested in adult women…”
BackgroundInfluential
Research works printed but not linked: 3
- Berlanda, 2016, Endometriosis: treatment of rectovaginal and bowel disease, UpToDate
- Lebovic, 2016, Endometriosis: surgical management of pelvic pain, UpToDate
- Royal College of Obstetricians and Gynaecologists, 2013, Fertility: Assessment and Treatment for People with Fertility Problems
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Effect of physical activity and exercise on endometriosis-associated symptoms: a systematic review
Tennfjord, M. K., Gabrielsen, R., & Tellum, T. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01500-4 · Cited by 192
“Advances in the understanding of endometriosis have expanded the focus on less invasive and nonpharmacological treatments [8, 9].”
BackgroundZakhari, A., Edwards, D., Ryu, M., Matelski, J. J., Bougie, O., & Murji, A. (2020) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2020.05.007 · Cited by 86
Possible role of microbiome in the pathogenesis of endometriosis
D’Alterio, M. N., GIULIANI, C., Scicchitano, F., Laganà, A. S., Oltolina, N., Sorrentino, F., Nappi, L., Orrù, G., & Angioni, S. L. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04788-2 · Cited by 51
Self-citationD’Alterio, M. N., Saponara, S., Agus, M., Laganà, A. S., Noventa, M., Loi, E. S., Féki, A., & Angioni, S. L. (2021) · Gynecological Surgery · doi:10.1186/s10397-021-01096-5 · Cited by 49
“Table 1 Characteristics and outcomes of the included studies evaluating the effect of the medical treatment for endometriosis on QoL First author and study period Type of study Sample size Range of age Type of medical treatment Type of endometriosis treated Results Instruments Ács et al. 2015 [50] Multicenter randomiz…”
MethodInfluentialSelf-citation
Metadata
- Authors
- Club, E. E. T. I., Alio, L., Angioni, S., Arena, S., Bartiromo, L., Bergamini, V, Berlanda, N., Bonin, C., Busacca, M., Candiani, M., Centini, G., D’Alterio, M. N., Di Cello, A., Exacoustos, C., Fedele, L., Frattaruolo, M. P., Incandela, D., Lazzeri, L., Luisi, S., Maiorana, A., Maneschi, F., Martire, F., Massarotti, C., Mattei, A., Muzii, L., Ottolina, J., Perandini, A., Perelli, F., Pino, I., Porpora, M. G., Raimondo, D., Remorgida, V, Seracchioli, R., Solima, E., Somigliana, E., Sorrenti, G., Venturella, R., Vercellini, P., Viganó, P., Vignali, M., Zullo, F., & Zupi, E.
- ORCID
- Angioni, S
- Bartiromo, L
- Bergamini, V
- Berlanda, N
- Candiani, M
- Centini, G
- D’Alterio, M N
- Fedele, L
- Frattaruolo, M P
- Incandela, D
- Lazzeri, L
- Luisi, S
- Maiorana, A
- Maneschi, F
- Martire, F
- Massarotti, C
- Muzii, L
- Ottolina, J
- Perandini, A
- Perelli, F
- Pino, I
- Porpora, M G
- Raimondo, D
- Remorgida, V
- Seracchioli, R
- Solima, E
- Somigliana, E
- Sorrenti, G
- Venturella, R
- Vercellini, P
- Vignali, M
- Zullo, F
- Zupi, E
- Venue
- Human Reproduction Open
- Publisher
- Oxford University Press (OUP)
- Published
- 2019
- Volume
- 2019
- Issue
- 3
- Pages
- hoz009-hoz009
- ISSN
- 2399-3529 (ISSN-L)
- PMC
- PMC6560357
- OpenAlex
- W2951373423
- Cited by
- 64
- References
- 155
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 10 · 2023: 6 · 2022: 14 · 2021: 14 · 2020: 10 · 2019: 1
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Human Reproduction Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc)
- Funders
- Institut Biochimique SA, Lugano, Switzerland
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, endometriosis treatment, infertility, endometrioma, CA125, estrogen-progestin, progestins, laparoscopy, controlled ovarian stimulation, intrauterine insemination, robot-assisted laparoscopic surgery, colorectal endometriosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement. https://app.cochat.ai/papers/10.1093/hropen/hoz009
- The paper
- Club, E. E. T. I., Alio, L., Angioni, S., Arena, S., Bartiromo, L., Bergamini, V, Berlanda, N., Bonin, C., Busacca, M., Candiani, M., Centini, G., D’Alterio, M. N., Di Cello, A., Exacoustos, C., Fedele, L., Frattaruolo, M. P., Incandela, D., Lazzeri, L., Luisi, S., . . . Zupi, E. (2019). When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement. Human Reproduction Open. https://doi.org/10.1093/hropen/hoz009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.